Pre-made Retifanlimab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Retifanlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Retifanlimab, designated as INCMGA 0012, is a humanised IgG4k anti-PD-1 monoclonal antibody, being developed by Incyte Corporation, under a license from.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-480-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Retifanlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
INN Name	Retifanlimab
Target	PDCD1/PD-1
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Preregistration
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	MacroGenics;Incyte Corporation;ZAI Lab
Conditions Approved	na
Conditions Active	Gastic cancers;Oesophageal cancer;Anal cancer;Endometrial cancer;Merkel cell carcinoma;Solid tumours;Colorectal cancer;Acute myeloid leukaemia;Squamous cell cancer;Non-small cell lung cancer;Glioblastoma;Head and neck cancer;Liposarcoma;Pancreatic cancer;Penile cancer;Soft tissue sarcoma
Conditions Discontinued	Haematological malignancies
Development Tech	na